Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

McGill University

$60,000.00

Identification of bioactive peptides from digestion of collagen hydrolysates

EF 2021-22

Résumé
Genacol Canada Corporation Inc. manufactures a bovine-sourced hydrolyzed collagen supplement (Genacol®Original Formula), which has shown efficacy in two separate clinical trials for reducing joint pain in subjects with osteoarthritis (OA). Following digestion, hydrolyzed collagen yields amino acids and peptides that can lead to the health promoting properties of the supplement. There is presently no information, however, regarding the peptide and amino acid profiles generated from the digestion of the Genacol supplement. Key information is also lacking regarding the collagen peptides reaching the joint and their mechanisms of action. In the present proposal, the profiles of the peptides and amino acids generated from digestive enzyme-mediated hydrolysis of the Genacol collagen product will be investigated using the dynamic simulated gut digestion model. To identify bioavailable peptides, the peptide fractions of the CH digests obtained from a dynamic simulated human GI model will be exposed to a human intestinal and liver cell co-culture system that simulates peptides that would reach the blood circulation. The peptides obtained from the co-culture will be studied for their anti-inflammatory effects in human OA articular cartilage tissue. Also, peptides generated during the simulated digestion studies will be investigated for their anti-inflammatory effects involving a co-culture of human intestinal cells, immune cells and intestinal dendritic cells involved in controlling pro-inflammatory factors that could also compromise joint health. This approach will help to ascertain the bioactive components contributing towards the health promoting properties of the Genacol collagen supplement and will aid in the development of more concentrated and potent hydrolyzed collagen products. Based on the profiles of bioavailable peptides shown to be bioactive in the OA cartilage tissue explants, Genacol will manufacture CH formulations enriched in those peptides that will be tested for their bioavailability and bioactivity in the above testing systems.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
535744-2018
Name nom
Kubow, Stan
Department département
Dietetics and Human Nutrition, School of
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2018
Award amount
60000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Installment
inst:4
Partie
1
Nb partie
5
Application title
Identification of bioactive peptides from digestion of collagen hydrolysates
Keyword
NSERC
Application summary
Genacol Canada Corporation Inc. manufactures a bovine-sourced hydrolyzed collagen supplement (Genacol®Original Formula), which has shown efficacy in two separate clinical trials for reducing joint pain in subjects with osteoarthritis (OA). Following digestion, hydrolyzed collagen yields amino acids and peptides that can lead to the health promoting properties of the supplement. There is presently no information, however, regarding the peptide and amino acid profiles generated from the digestion of the Genacol supplement. Key information is also lacking regarding the collagen peptides reaching the joint and their mechanisms of action. In the present proposal, the profiles of the peptides and amino acids generated from digestive enzyme-mediated hydrolysis of the Genacol collagen product will be investigated using the dynamic simulated gut digestion model. To identify bioavailable peptides, the peptide fractions of the CH digests obtained from a dynamic simulated human GI model will be exposed to a human intestinal and liver cell co-culture system that simulates peptides that would reach the blood circulation. The peptides obtained from the co-culture will be studied for their anti-inflammatory effects in human OA articular cartilage tissue. Also, peptides generated during the simulated digestion studies will be investigated for their anti-inflammatory effects involving a co-culture of human intestinal cells, immune cells and intestinal dendritic cells involved in controlling pro-inflammatory factors that could also compromise joint health. This approach will help to ascertain the bioactive components contributing towards the health promoting properties of the Genacol collagen supplement and will aid in the development of more concentrated and potent hydrolyzed collagen products. Based on the profiles of bioavailable peptides shown to be bioactive in the OA cartilage tissue explants, Genacol will manufacture CH formulations enriched in those peptides that will be tested for their bioavailability and bioactivity in the above testing systems.